Report cover image

2025 United States Antiviral Drugs Market Revenue Opportunities Report

Published Sep 01, 2025
Length 51 Pages
SKU # WSR20382797

Description

The 2025 United States Antiviral Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)

The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.

Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)

The report features written analysis and market size statistics on opportunities created in the Antiviral Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,

The four largest companies actively participating in the U.S. antiviral drugs market are AbbVie, Gilead Sciences, Merck & Co., and Johnson & Johnson. AbbVie is notable for its leading hepatitis C antiviral therapy, MAVYRET, recently FDA-approved for acute and chronic hepatitis C infections with high cure rates. Gilead Sciences dominates the HIV segment with its flagship drug Biktarvy, generating $13.42 billion in 2024 U.S. sales, and maintains a strong pipeline with preclinical programs targeting herpes and influenza viruses.

Merck & Co. achieved significant revenues from antiviral medications like Gardasil (HPV vaccine) and Lagevrio (COVID-19 treatment), with extensive R&D investment fueling innovation. Johnson & Johnson contributes through its diversified antiviral portfolio and presence in both branded and generic antiviral drugs markets. These companies benefit from robust U.S. healthcare infrastructure, supportive FDA approvals, and growing demand driven by chronic viral infections such as HIV, hepatitis, and herpes.

Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.

This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.

Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.

Table of Contents

51 Pages
A. Definitions
A1. Market Definition
A2. Market Segmentation
A3. Industry Opportunities-Industry1
A4. Industry Opportunities-Industry2
A5. Industry Opportunities-Industry3
B. Total Addressable Market (TAM)
B1. TAM-Player 1/4
B2. TAM-Player 2/4
B3. TAM-Player 3/4
B4. TAM-Player 4/4
C. Serviceable Addressable Market (SAM)
C1. SAM-Player 1/4
C2. SAM-Player 2/4
C3. SAM-Player 3/4
C4. SAM-Player 4/4
D. Serviceable Obtainable Market (SOM)
D1. SOM-Player 1/4
D2. SOM-Player 2/4
D3. SOM-Player 3/4
D4. SOM-Player 4/4
E. Appendix

Search Inside Report

How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.